Neoadjuvant treatment improves survival in esophageal cancer patients

A retrospective analysis involving 645 patients with cT2 staged adenocarcinomas indicated that neoadjuvant treatment followed by surgery (nat/s) yields significantly better overall survival compared to primary surgery (ps). Median overall survival was 114.0 months for nat/s versus 51.0 months for ps in the cT2cnany cohort. Additionally, nat/s was associated with improved disease-free survival in cT2cn0 patients. Notably, 38.1% of cT2cnany and 34.2% of cT2cn0 patients were found to be understaged.